Association between Body Mass Index and Survival Outcome in Metastatic Cancer Patients Treated by Immunotherapy: Analysis of a French Retrospective Cohort
The response to immunotherapy has been little investigated in overweight and obese cancer patients. We evaluated the relationships between BMI, toxicity, and survival in patients treated by immunotherapy for metastatic cancer. We included metastatic cancer patients treated by immunotherapy between J...
Gespeichert in:
| Veröffentlicht in: | Cancers 2021-05, Vol.13 (9), p.2200 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 9 |
| container_start_page | 2200 |
| container_title | Cancers |
| container_volume | 13 |
| creator | Collet, Laetitia Delrieu, Lidia Bouhamama, Amine Crochet, Hugo Swalduz, Aurélie Nerot, Alexandre Marchal, Timothée Chabaud, Sylvie Heudel, Pierre Etienne |
| description | The response to immunotherapy has been little investigated in overweight and obese cancer patients. We evaluated the relationships between BMI, toxicity, and survival in patients treated by immunotherapy for metastatic cancer. We included metastatic cancer patients treated by immunotherapy between January 2017 and June 2020 at the Centre Léon Bérard. In total, 272 patients were included: 64% men and 36% women, with a median age of 61.4 years. BMI ≥ 25 in 34.2% and 50% had non-small cell lung cancer (n = 136). Most received monotherapy, with nivolumab in 41.9% and pembrolizumab in 37.9%. Toxicity, mostly dysthyroiditis, occurred in 41%. Median overall survival (OS), estimated by Kaplan–Meier analysis, was significantly longer for patients with a BMI ≥ 25 than for those with a BMI < 25 (24.8 versus 13.7 months HR = 0.63; 95% CI 0.44–0.92, p = 0.015), and for patients experiencing toxicity than for those without toxicity (NR versus 7.8 months, HR = 0.22; 95% CI 0.15–0.33, p < 0.001). Adjusted OS was associated with toxicity, and the occurrence of toxicity was associated with sex and histological features but not with BMI. Thus, being overweight and experiencing toxicity was associated with longer overall survival in patients treated by immunotherapy. More attention should be paid to body composition in the care of cancer patients. |
| doi_str_mv | 10.3390/cancers13092200 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8124396</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2536480711</sourcerecordid><originalsourceid>FETCH-LOGICAL-c398t-3080ebbee96b5b3d53781957fdc62f7517bbbcbb6bcee08b5f86163bc16afa713</originalsourceid><addsrcrecordid>eNpdUU1v1DAQtRCIVqVnriNx4bLUHxs74YC0rNqyUqsiKGfLdiasq8RebGchf4Vf2yytEHQuM6N58-bpDSGvGX0nREPPnAkOU2aCNpxT-owcc6r4Qspm-fyf-oic5nxH5xCCKalekiOxpFLIhh-T36uco_Om-BjAYvmJGOBjbCe4NjnDJrT4C0xo4euY9n5vergZi4sDgg9wjcXkMu86WP_RAp_nBkPJcJvQFGzBTrAZhjHEssVkdtN7WAXTT9lniB0YuEgY3Ba-YEkx79AVv0dYx21M5RV50Zk-4-ljPiHfLs5v158WVzeXm_XqauFEU5eFoDVFaxEbaSsr2kqomjWV6loneacqpqy1zlppHSKtbdXVkklhHZOmM4qJE_LhgXc32gFbN-tPpte75AeTJh2N1_9Pgt_q73Gva8aXopEzwdtHghR_jJiLHnx22PcmYByz5pWQy5oqdrj15gn0Lo5pduSA4jWvKsEPqLMHlJtNyQm7v2IY1YfX6yevF_cXk6VL</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2528255321</pqid></control><display><type>article</type><title>Association between Body Mass Index and Survival Outcome in Metastatic Cancer Patients Treated by Immunotherapy: Analysis of a French Retrospective Cohort</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Collet, Laetitia ; Delrieu, Lidia ; Bouhamama, Amine ; Crochet, Hugo ; Swalduz, Aurélie ; Nerot, Alexandre ; Marchal, Timothée ; Chabaud, Sylvie ; Heudel, Pierre Etienne</creator><creatorcontrib>Collet, Laetitia ; Delrieu, Lidia ; Bouhamama, Amine ; Crochet, Hugo ; Swalduz, Aurélie ; Nerot, Alexandre ; Marchal, Timothée ; Chabaud, Sylvie ; Heudel, Pierre Etienne</creatorcontrib><description>The response to immunotherapy has been little investigated in overweight and obese cancer patients. We evaluated the relationships between BMI, toxicity, and survival in patients treated by immunotherapy for metastatic cancer. We included metastatic cancer patients treated by immunotherapy between January 2017 and June 2020 at the Centre Léon Bérard. In total, 272 patients were included: 64% men and 36% women, with a median age of 61.4 years. BMI ≥ 25 in 34.2% and 50% had non-small cell lung cancer (n = 136). Most received monotherapy, with nivolumab in 41.9% and pembrolizumab in 37.9%. Toxicity, mostly dysthyroiditis, occurred in 41%. Median overall survival (OS), estimated by Kaplan–Meier analysis, was significantly longer for patients with a BMI ≥ 25 than for those with a BMI < 25 (24.8 versus 13.7 months HR = 0.63; 95% CI 0.44–0.92, p = 0.015), and for patients experiencing toxicity than for those without toxicity (NR versus 7.8 months, HR = 0.22; 95% CI 0.15–0.33, p < 0.001). Adjusted OS was associated with toxicity, and the occurrence of toxicity was associated with sex and histological features but not with BMI. Thus, being overweight and experiencing toxicity was associated with longer overall survival in patients treated by immunotherapy. More attention should be paid to body composition in the care of cancer patients.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers13092200</identifier><identifier>PMID: 34063692</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Body composition ; Body mass index ; Body weight ; Cancer therapies ; Chemotherapy ; Data collection ; Data mining ; Immunotherapy ; Inflammation ; Kidney cancer ; Lung cancer ; Melanoma ; Metastases ; Metastasis ; Non-small cell lung carcinoma ; Obesity ; Overweight ; Patients ; Pembrolizumab ; Population ; Small cell lung carcinoma ; Toxicity ; Tumors ; Variables</subject><ispartof>Cancers, 2021-05, Vol.13 (9), p.2200</ispartof><rights>2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 by the authors. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c398t-3080ebbee96b5b3d53781957fdc62f7517bbbcbb6bcee08b5f86163bc16afa713</citedby><cites>FETCH-LOGICAL-c398t-3080ebbee96b5b3d53781957fdc62f7517bbbcbb6bcee08b5f86163bc16afa713</cites><orcidid>0000-0002-2155-549X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124396/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124396/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids></links><search><creatorcontrib>Collet, Laetitia</creatorcontrib><creatorcontrib>Delrieu, Lidia</creatorcontrib><creatorcontrib>Bouhamama, Amine</creatorcontrib><creatorcontrib>Crochet, Hugo</creatorcontrib><creatorcontrib>Swalduz, Aurélie</creatorcontrib><creatorcontrib>Nerot, Alexandre</creatorcontrib><creatorcontrib>Marchal, Timothée</creatorcontrib><creatorcontrib>Chabaud, Sylvie</creatorcontrib><creatorcontrib>Heudel, Pierre Etienne</creatorcontrib><title>Association between Body Mass Index and Survival Outcome in Metastatic Cancer Patients Treated by Immunotherapy: Analysis of a French Retrospective Cohort</title><title>Cancers</title><description>The response to immunotherapy has been little investigated in overweight and obese cancer patients. We evaluated the relationships between BMI, toxicity, and survival in patients treated by immunotherapy for metastatic cancer. We included metastatic cancer patients treated by immunotherapy between January 2017 and June 2020 at the Centre Léon Bérard. In total, 272 patients were included: 64% men and 36% women, with a median age of 61.4 years. BMI ≥ 25 in 34.2% and 50% had non-small cell lung cancer (n = 136). Most received monotherapy, with nivolumab in 41.9% and pembrolizumab in 37.9%. Toxicity, mostly dysthyroiditis, occurred in 41%. Median overall survival (OS), estimated by Kaplan–Meier analysis, was significantly longer for patients with a BMI ≥ 25 than for those with a BMI < 25 (24.8 versus 13.7 months HR = 0.63; 95% CI 0.44–0.92, p = 0.015), and for patients experiencing toxicity than for those without toxicity (NR versus 7.8 months, HR = 0.22; 95% CI 0.15–0.33, p < 0.001). Adjusted OS was associated with toxicity, and the occurrence of toxicity was associated with sex and histological features but not with BMI. Thus, being overweight and experiencing toxicity was associated with longer overall survival in patients treated by immunotherapy. More attention should be paid to body composition in the care of cancer patients.</description><subject>Body composition</subject><subject>Body mass index</subject><subject>Body weight</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Data collection</subject><subject>Data mining</subject><subject>Immunotherapy</subject><subject>Inflammation</subject><subject>Kidney cancer</subject><subject>Lung cancer</subject><subject>Melanoma</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Non-small cell lung carcinoma</subject><subject>Obesity</subject><subject>Overweight</subject><subject>Patients</subject><subject>Pembrolizumab</subject><subject>Population</subject><subject>Small cell lung carcinoma</subject><subject>Toxicity</subject><subject>Tumors</subject><subject>Variables</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdUU1v1DAQtRCIVqVnriNx4bLUHxs74YC0rNqyUqsiKGfLdiasq8RebGchf4Vf2yytEHQuM6N58-bpDSGvGX0nREPPnAkOU2aCNpxT-owcc6r4Qspm-fyf-oic5nxH5xCCKalekiOxpFLIhh-T36uco_Om-BjAYvmJGOBjbCe4NjnDJrT4C0xo4euY9n5vergZi4sDgg9wjcXkMu86WP_RAp_nBkPJcJvQFGzBTrAZhjHEssVkdtN7WAXTT9lniB0YuEgY3Ba-YEkx79AVv0dYx21M5RV50Zk-4-ljPiHfLs5v158WVzeXm_XqauFEU5eFoDVFaxEbaSsr2kqomjWV6loneacqpqy1zlppHSKtbdXVkklhHZOmM4qJE_LhgXc32gFbN-tPpte75AeTJh2N1_9Pgt_q73Gva8aXopEzwdtHghR_jJiLHnx22PcmYByz5pWQy5oqdrj15gn0Lo5pduSA4jWvKsEPqLMHlJtNyQm7v2IY1YfX6yevF_cXk6VL</recordid><startdate>20210503</startdate><enddate>20210503</enddate><creator>Collet, Laetitia</creator><creator>Delrieu, Lidia</creator><creator>Bouhamama, Amine</creator><creator>Crochet, Hugo</creator><creator>Swalduz, Aurélie</creator><creator>Nerot, Alexandre</creator><creator>Marchal, Timothée</creator><creator>Chabaud, Sylvie</creator><creator>Heudel, Pierre Etienne</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2155-549X</orcidid></search><sort><creationdate>20210503</creationdate><title>Association between Body Mass Index and Survival Outcome in Metastatic Cancer Patients Treated by Immunotherapy: Analysis of a French Retrospective Cohort</title><author>Collet, Laetitia ; Delrieu, Lidia ; Bouhamama, Amine ; Crochet, Hugo ; Swalduz, Aurélie ; Nerot, Alexandre ; Marchal, Timothée ; Chabaud, Sylvie ; Heudel, Pierre Etienne</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c398t-3080ebbee96b5b3d53781957fdc62f7517bbbcbb6bcee08b5f86163bc16afa713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Body composition</topic><topic>Body mass index</topic><topic>Body weight</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Data collection</topic><topic>Data mining</topic><topic>Immunotherapy</topic><topic>Inflammation</topic><topic>Kidney cancer</topic><topic>Lung cancer</topic><topic>Melanoma</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Non-small cell lung carcinoma</topic><topic>Obesity</topic><topic>Overweight</topic><topic>Patients</topic><topic>Pembrolizumab</topic><topic>Population</topic><topic>Small cell lung carcinoma</topic><topic>Toxicity</topic><topic>Tumors</topic><topic>Variables</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Collet, Laetitia</creatorcontrib><creatorcontrib>Delrieu, Lidia</creatorcontrib><creatorcontrib>Bouhamama, Amine</creatorcontrib><creatorcontrib>Crochet, Hugo</creatorcontrib><creatorcontrib>Swalduz, Aurélie</creatorcontrib><creatorcontrib>Nerot, Alexandre</creatorcontrib><creatorcontrib>Marchal, Timothée</creatorcontrib><creatorcontrib>Chabaud, Sylvie</creatorcontrib><creatorcontrib>Heudel, Pierre Etienne</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Collet, Laetitia</au><au>Delrieu, Lidia</au><au>Bouhamama, Amine</au><au>Crochet, Hugo</au><au>Swalduz, Aurélie</au><au>Nerot, Alexandre</au><au>Marchal, Timothée</au><au>Chabaud, Sylvie</au><au>Heudel, Pierre Etienne</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association between Body Mass Index and Survival Outcome in Metastatic Cancer Patients Treated by Immunotherapy: Analysis of a French Retrospective Cohort</atitle><jtitle>Cancers</jtitle><date>2021-05-03</date><risdate>2021</risdate><volume>13</volume><issue>9</issue><spage>2200</spage><pages>2200-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>The response to immunotherapy has been little investigated in overweight and obese cancer patients. We evaluated the relationships between BMI, toxicity, and survival in patients treated by immunotherapy for metastatic cancer. We included metastatic cancer patients treated by immunotherapy between January 2017 and June 2020 at the Centre Léon Bérard. In total, 272 patients were included: 64% men and 36% women, with a median age of 61.4 years. BMI ≥ 25 in 34.2% and 50% had non-small cell lung cancer (n = 136). Most received monotherapy, with nivolumab in 41.9% and pembrolizumab in 37.9%. Toxicity, mostly dysthyroiditis, occurred in 41%. Median overall survival (OS), estimated by Kaplan–Meier analysis, was significantly longer for patients with a BMI ≥ 25 than for those with a BMI < 25 (24.8 versus 13.7 months HR = 0.63; 95% CI 0.44–0.92, p = 0.015), and for patients experiencing toxicity than for those without toxicity (NR versus 7.8 months, HR = 0.22; 95% CI 0.15–0.33, p < 0.001). Adjusted OS was associated with toxicity, and the occurrence of toxicity was associated with sex and histological features but not with BMI. Thus, being overweight and experiencing toxicity was associated with longer overall survival in patients treated by immunotherapy. More attention should be paid to body composition in the care of cancer patients.</abstract><cop>Basel</cop><pub>MDPI AG</pub><pmid>34063692</pmid><doi>10.3390/cancers13092200</doi><orcidid>https://orcid.org/0000-0002-2155-549X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2021-05, Vol.13 (9), p.2200 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8124396 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central; PubMed Central Open Access |
| subjects | Body composition Body mass index Body weight Cancer therapies Chemotherapy Data collection Data mining Immunotherapy Inflammation Kidney cancer Lung cancer Melanoma Metastases Metastasis Non-small cell lung carcinoma Obesity Overweight Patients Pembrolizumab Population Small cell lung carcinoma Toxicity Tumors Variables |
| title | Association between Body Mass Index and Survival Outcome in Metastatic Cancer Patients Treated by Immunotherapy: Analysis of a French Retrospective Cohort |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T06%3A22%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20between%20Body%20Mass%20Index%20and%20Survival%20Outcome%20in%20Metastatic%20Cancer%20Patients%20Treated%20by%20Immunotherapy:%20Analysis%20of%20a%20French%20Retrospective%20Cohort&rft.jtitle=Cancers&rft.au=Collet,%20Laetitia&rft.date=2021-05-03&rft.volume=13&rft.issue=9&rft.spage=2200&rft.pages=2200-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers13092200&rft_dat=%3Cproquest_pubme%3E2536480711%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2528255321&rft_id=info:pmid/34063692&rfr_iscdi=true |